At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 32 enrolled
Drug / intervention
RVP-001 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Center, Double-Blinded, Phase 1a Randomized Study to Evaluate Safety and Pharmacokinetics of a New Manganese Based Magnetic Resonance Imaging (MRI) Contrast Agent, RVP-001, in Healthy Adult Subjects
In Brief
A Phase 1 clinical trial evaluating RVP-001 and Placebo for Healthy. Completed, enrolled 32 participants across 1 site.
Detailed Summary
The objectives of this trial are: 1. To evaluate the safety and tolerability of single ascending doses of RVP-001 in healthy adult volunteers 2. To determine the pharmacokinetics and elimination of RVP-001 in healthy adult volunteers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), Quotient Sciences
Timeline
Phase 1CompletedFinished
2023202420252026
Enrollment StartMay 2022
First PostedJun 2022
Primary CompletionJul 2022
Study CompletionAug 2022
TodayJul 2026
First PostedJun 10, 2022
Enrollment StartMay 18, 2022
Primary CompletionJul 22, 2022
Study CompletionAug 22, 2022
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 4.1 years ago
Interventions
RVP-001drug
Intravenous administration of RVP-001
Placebodrug
Intravenous administration of saline placebo